Not mentioned much on the call was newly approved cancer drug ERIVEDGE which is licensed from Curis $CRIS - but sales since launch in late January were reported as being $5.5m for the quarter, meaning that royalties to Curis are miniscule at this point (most estimates I have seen indicate mid single digit royalties).
Access the entire transcript at Morningstar.
Check out all the companies I cover, with my new real-time valuation updates on the Stocks page.
""et me just briefly comment on the status of the Illumina transactions. Based on the public information available to us we believe that our offer price of $51 per share is a full and fair offer and extremely attractive to Illumina shareholders. As we have said earlier, our price point remains a negotiated transaction and we would in fact consider any additional information which shows value we can't see at this point. Unfortunately, however, Illumina has not engaged in any discussions with us and we firmly believe that our present offer is more than adequate to serve as a basis to begin a negotiation with Illumina. Again, let me be very clear here there is no reason for us whatsoever to increase our offer unless we get into negotiations and so far this is not the case".
"I think everything else in case of Illumina let me stipulate once again our offer is fair and full ($51) that's what we have on the table without additional information coming from negotiation situation there is no way that we increase that."